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Immunization with a whole-cell sonicate vaccine of Helicobacter
felis in conjunction with cholera toxin as a mucosal adjuvant
induces long-term protective immunity in a majority of laboratory
mice. We have combined gene expression profiling and immuno-
histochemical analysis on a set of immunized animals to better
understand the mechanism of protection. The stomachs of pro-
tected animals exhibited a strikingly different transcriptional pro-
file compared with those of nonprotected or control mice, indicat-
ing that vaccination targets the appropriate site and leaves a
molecular signature. Among the genes whose up-regulation is
significantly correlated with protection are a number of adipocyte-
specific factors. These include the fat-cell-specific cytokines adip-
sin, resistin, and adiponectin and the adipocyte surface marker
CD36. Interestingly, potentially protective T and B lymphocytes can
be found embedded in the adipose tissue surrounding protected
stomachs but never in control or unprotected stomachs. Adipsin-
specific immunohistochemical staining of protected stomach sec-
tions further revealed molecular cross-talk between adjacent lym-
phoid and adipose cell populations. We propose a mechanism of
protection that involves the effector responses of either or both
lymphocyte subclasses as well as the previously unappreciated
paracrine functions of adipose tissue surrounding the resident
lymphocytes.
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Gastric infection with the bacterium Helicobacter pylori isassociated with the development of acute chronic gastritis,
peptic ulcer disease, and two gastric malignancies, adenocarci-
noma and mucosa-associated lymphoid tissue (MALT) lym-
phoma (1–4). Therefore, successful eradication of H. pylori from
infected populations is considered an important public health
goal. The currently used eradication strategy focuses on treat-
ment of those individuals that display overt disease symptoms
with a combination of two to three antibiotics and a proton pump
inhibitor (5). However, the increasing prevalence of antibiotic
resistance (6), the lack of protection against reinfection, and the
high cost limit the usefulness of this strategy for control of H.
pylori-related diseases. The development of a prophylactic vac-
cine with possible therapeutic applications is widely viewed as a
promising complementary approach.
The first animal model for Helicobacter infection became
available in 1990 with the demonstration that Helicobacter felis
could colonize the murine stomach and induce chronic active
gastritis (7). Using this model, Chen et al. (8) were able to
demonstrate that immunization with a whole-cell H. felis soni-
cate oral vaccine in combination with cholera toxin as a mucosal
adjuvant can protect the host from later challenge with large
viable doses of the same strain. Moreover, the organism load of
an existing H. felis infection could also be significantly reduced
with the same vaccine regimen, thereby demonstrating the effect
of therapeutic immunization (9). Observations made by using
the H. felis model system were subsequently confirmed by using
a mouse-adapted strain of H. pylori (10, 11).
The protective mechanism of this and other vaccination
strategies against H. pylori is currently being actively investigated.
Due to the localization of H. pylori in the mucus layer of the
gastric epithelium, it was initially assumed that protective im-
munity was mediated by IgA secreted into the stomach lumen.
Evidence from challenge experiments using B lymphocyte-
deficient mouse strains has ruled out this possibility, because
these animals retain the same level of protection as wild-type
mice (12–14). Additional experiments have shown that MHC
I-deficient mice, which lack the CD8 population of T cells, are
fully protected, whereas MHC II deficiency results in lack of
protection (12, 15). Hence, successful immunization against H.
pylori seems to depend on the CD4 population of T cells.
Adoptive transfer experiments of Helicobacter-specific Th1 and
Th2 cells further indicate that only a Th2-polarized response can
mediate protective immunity (16). In contrast, colonization of
the human stomach with H. pylori induces a proinflammatory
Th1 response characterized by high levels of IFN and IL-12,
which is clearly ineffective in combating infection (17, 18) and
does not prevent reinfection after antibiotic therapy. Several
Helicobacter vaccine protocols effective in small animal models
have been tested in human trials (19–23); however, none of them
was successful in triggering a strong systemic response in the
majority of vaccinees, suggesting that large discrepancies exist
between murine and human hosts.
By combining the well characterized whole-cell sonicate
cholera toxin vaccine (8, 14, 24–26) with gene expression
profiling of protected vs. unprotected stomachs, we attempt to
shed light on the issue of protective immunity from a very
different experimental angle. As shown earlier, this vaccine
protocol stimulates long-term, probably life-long, immunity (25)
and prevents the pathological changes normally associated with
chronic Helicobacter infection of the stomach (26). Here we
present data indicating that the protective response occurs
locally in the gastric mucosal environment, is clearly reflected at
the gene expression level, and involves a number of previously
recognized as well as novel cell types.
Materials and Methods
Animals. Specific pathogen-free female BALBc mice were ob-
tained from the Animal Resource Centre, Canning Vale, Aus-
tralia, at 7 wk of age. All protocols involving animal experimen-
tation were approved by the Animal Care and Ethics Committee
at the University of New South Wales.
Immunization and Infection Experiments. The protocol for prophy-
lactic immunization with 1 mg of H. felis sonicate and 10 g of
cholera toxin (Sigma) was described previously (26). For chal-
lenge at 2 mo postimmunization, mice were infected intragas-
trically with 0.1 ml of viable H. felis bacterial culture (108
bacteria) twice during a 3-d period.
Abbreviation: MALT, mucosa-associated lymphoid tissue.
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Sampling and Histological Assessment. Mice were killed 22 mo after
bacterial challenge, and the stomachs were removed. Half of
each stomach was fixed in 10% buffered formalin before em-
bedding in paraffin, and the rest was snap-frozen in liquid
nitrogen for RNA preparation. Sections were cut and stained
with May–Grünwald–Giemsa to assess bacterial colonization
and with hematoxylineosin for histological analysis.
Microarray Analysis. Gene expression profiling with 38,000 ele-
ment-spotted murine cDNA microarrays was performed as
described (27). Microarray data were stored in the Stanford
Microarray Database (28). Data were filtered with respect to
spot quality (spots with regression correlations 0.6 were omit-
ted) and data distribution (genes whose log2 of redgreen
normalized ratio is more than 2 standard deviations away from
the mean in at least five arrays were selected) before clustering.
Only genes for which information was available for 70% of
arrays were included. Data were log2 transformed and analyzed
by using CLUSTER and TREEVIEW (29). Statistical analysis was
done by using the significance analysis of microarrays algorithm
(30). Data from all of the arrays used in this paper are available
at http:genome-www4.stanford.eduMicroArraySMD.
Immunohistochemistry. Sequential 4-m paraffin sections were
stained with antibodies specific for the following murine anti-
gens: CD45RB220 on B cells (PharMingenBD Biosciences),
CD3 on T cells (Biomeda, Foster City, CA), adipsin on adipo-
cytes (Santa Cruz Biotechnology) and F480 on macrophages
(Abcam Limited, Cambridge, U.K.). The detection was per-
formed by using biotinylated secondary antibodies in combina-
tion with horseradish-peroxidase-coupled streptavidin (Jackson
ImmunoResearch) and the substrate DAB (Research Genetics
Invitrogen, Carlsbad, CA). All sections were counterstained with
hematoxylin, dehydrated, and mounted by using synthetic non-
aqueous mounting medium. A Zeiss Axiophot microscope
equipped with an AxioCam digital camera and AXIOVISION 3.1.
software (Zeiss) were used for documentation.
Results
Gene Expression Profiling of Control, Infected, and Immunized Mice.
We analyzed 32 mice in the present study: of these, 5 belonged
to an untreated control group (group A), 8 were infected with
H. felis (group B), and 19 were immunized with a whole-cell
sonicate of H. felis and cholera toxin before challenge with H.
felis (group C) 2 mo later. The mice were then maintained for 22
mo to allow sufficient time for development of Helicobacter-
specific pathology before histological and gene expression anal-
ysis. Bacterial colonization was assessed by culture, histology,
and ureB-specific RT-PCR (data not shown). Of the 19 immu-
nized animals, only 5 were colonized, suggesting that the vaccine
was protective in 74% of the cases. In contrast, all H. pylori-
challenged unvaccinated animals were colonized successfully.
Colonization in both groups was most dense in the antral region
and in the antralbody transitional zone.
RNA was isolated from whole stomachs of all 32 animals and
hybridized to a 38,000-element murine cDNA microarray. A
hierarchical clustering algorithm was used to group genes and
samples in an ‘‘unsupervised’’ fashion on the basis of similarities
of gene expression (29). The relationships among the samples are
summarized in a dendrogram (Fig. 1). All 13 colonized animals
cluster together tightly and form one arm of the dendrogram.
Interestingly, this branch contains both the eight challenged
animals that did not receive the vaccine (black) and the five
animals that were immunized unsuccessfully (the ‘‘unprotected’’
subgroup, depicted in red). The control animals (in blue) form
a separate branch that also contains four mice of the ‘‘protected’’
subgroup of immunized animals. All other protected animals
(green) cluster together in a third branch. Infection status is
therefore revealed as a strong force in driving the clustering.
Among the genes up-regulated in the infected group were
lymphocyte-specific surface markers and signaling molecules
previously linked to the development of MALT pathology such
as CD52 and calgranulin A (27). Similarly, a number of gastric
enzymes and hormones are specifically down-regulated in this
group, most notably somatostatin, gastrin, phospholipase A2,
Fig. 1. Molecular signature of immunized, Helicobacter-infected, and control murine stomachs. Data are a measure of relative gene expression and represent
the quotient of the hybridization of the fluorescent cDNA probe prepared from each stomach sample compared with a reference pool. Red and green represent
high and low experimental samplereference ratios, respectively (see scale bar). Gray signifies technically inadequate or missing data. The color coding of array
names is indicated in the box. Selected gene clusters are designated and described briefly.
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and progastricsin. This trend most likely reflects the massive loss
of certain epithelial and endocrine cell types (atrophy) that is a
common feature of Helicobacter-induced pathology. In addition,
the fact that a majority of immunized protected animals forms
a distinct branch suggests that the immunization procedure alone
also acts as a strong driving force, indicating that the used
vaccine regimen elicits an immune response locally at the site of
potential infection.
Statistical Comparison of the Gene Expression Profiles of Protected
and Unprotected Stomachs. The lack of protective immunity in
roughly one-fourth of the vaccinated animals turned out to be an
asset in the comparison of protected with unprotected stomachs.
In a statistical analysis using the multiclass function of the
significance analysis of microarrays algorithm (30), three groups
(control, immunizedprotected, and immunizedunprotected)
were subjected to a three-way comparison. The eight animals of
the infected unvaccinated group were excluded from this anal-
ysis, because they did not contribute additional information
(data not shown). Seven hundred and seventy-six genes (Fig. 2A)
differed significantly between at least two of the three groups
when a 5% false positive discovery rate cutoff was used. The
majority of these genes distinguish the infected from all other
samples and have been discussed (27). All significant genes were
converted to a CLUSTER-readable format by the program
SAMSTER (downloadable from http:falkow.stanford.edu
whatwedosoftware).
Two up-regulated gene clusters were identified that contain
genes whose expression correlates very tightly with protection
(Fig. 2B). One of them represents a lymphocyte signature with
mostly B cell-specific genes such as the Ig genes encoding the ,
, , and joining chains. The same cluster also includes the B cell
surface marker CD40 as well as integrin 7, a component of the
homing receptor of both B and T cells for mucosal surfaces of
the gastrointestinal tract. Whereas this cluster correlates well
with protection, earlier experiments suggested that its up-
regulation is not sufficient for protection: the same lymphocyte
signature is found in stomachs from which H. pylori has been
eradicated by antibiotic therapy, but these cured mice can be
reinfected readily even with the same Helicobacter strain (A.M.,
J.O., A.L., and S.F., unpublished data).
The other cluster correlating tightly with protection contains
a number of genes specifically expressed in fat cells
adipocytes. Among these are three adipocyte-specific cyto-
kines, the so-called ‘‘adipokines,’’ adipsin, resistin, and adi-
ponectin (formerly known as adipocyte complement-related
protein of 30 kDa, or Acrp30). Other genes in this cluster
include the fat cell-specific fatty acid-binding protein 4, car-
bonic anhydrase 3, and the surface marker CD36. In general,
fat cell-specific genes are up-regulated in protected, but
down-regulated in unprotected, immunized stomachs relative
to the controls. The angiogenesis promoter angiopoietin 2 is
also contained in this cluster, and fat tissue has previously been
shown to be a major source of this secreted protein. Indeed,
induction of angiopoietin 2 by the adipokine leptin has been
shown to trigger the remodeling of fat tissue microvasculature
(31). Another interesting gene expressed strongly in protected
stomachs encodes histidine decarboxylase, a signature protein
of enterochromaffin-like cells, an important endocrine cell
type of the stomach. Histidine decarboxylase is a key enzyme
in the histamine synthesis pathway, and secreted histamine in
turn modulates gastric acid secretion.
Histological Comparison of Murine Stomach Sections. The described
differences in overall gastric gene expression suggest dramatic
differences in cellular composition among the four groups of the
study. In order to discern which additional cell types are present
due to the immunization procedure and where they are localized
in the stomach, we assessed the overall stomach histology on
hematoxylineosin-stained sections for representatives of every
group (Fig. 3). As reported (32), life-long infection of BALBc
mice with either H. pylori or H. felis results in a MALT-type
pathology (Fig. 3 C and D) characterized by massive lymphocytic
infiltration, destruction of the gastric epithelium, and, in a
minority of cases, progression to MALT lymphoma. As sug-
gested by the gene expression results, no morphological differ-
ences were observed between colonized mice that had received
the vaccine (immunizedunprotected) and those that had been
infected without prior vaccination.
Uninfected stomachs are usually embedded in a layer of fat tissue
(Fig. 3A, indicated by thin arrow), the thickness of which varies
slightly from individual to individual and from section to section. In
contrast, infected stomachs are usually surrounded by a strongly
diminished or even entirely disrupted fat layer, correlating with the
loss of adipocyte-specific gene expression observed in infected
stomachs relative to controls (Fig. 2). In contrast, protected stom-
achs exhibit a thicker fat layer than controls (Fig. 3 A and B), again
confirming the gene expression results (Fig. 2).
Furthermore, the fat tissue of protected stomachs contains
clusters of lymphocytes that cannot be found in controls (thick
arrow). The striking presence of these clusters correlates with
protection and is very likely reflected by the lymphocyte-specific
gene cluster shown in Fig. 2.
Immunohistochemical Analysis of Protected and Unprotected Stom-
achs. On the basis of the assumption that adipose tissue functions
are crucial in protective immunity against Helicobacter and the
observation that lymphocytic clusters reside in fat depots in
protected stomachs, we hypothesized that there should be cross-
talk between the two tissue types. The secreted adipokines are
likely mediators of cross-talk with lymphocytes and have previ-
ously been shown to play this role (33); therefore, adipsin was
Fig. 2. Three-way significance analysis of microarrays comparison of pro-
tected, unprotected, and control stomachs. (A) Overview of all 776 genes that
differ significantly between at least two of the three groups when a 5% false
positive discovery rate cutoff was used. (B) Two enlarged sections are shown.
(Upper) Genes that are up-regulated in both the unprotected and protected
subgroups of animals compared with the controls, albeit much stronger in the
former group. (Lower) Genes that are up-regulated in the protected vs.
unprotected or control groups. Selected genes are designated. The color
coding of arrays and genes is indicated in the boxes.









chosen as a representative member of this group. Sequential
4-m sections of paraffin-embedded stomach tissue were stained
with an adipsin-specific antibody as well as antibodies against
known marker proteins for T cells (CD3), B cells (B220
CD45R), and macrophages (F480) to determine the cellular
composition of lymphocytic clusters in protected stomachs
vs. MALT-type lymphoid aggregates in unprotected stomachs
(Fig. 4).
A representative cluster embedded in adipose tissue of a
protected stomach is shown in Fig. 4A Top: whereas very few
cells stain strongly with the B cell-specific anti-B220 antibody,
the vast majority stain positive for CD3, revealing a BT cell ratio
of 1 in 4. As expected, both markers show a characteristic
membrane-staining pattern consistent with the surface localiza-
tion of both antigens. No macrophages are present in the cluster.
The surrounding fat tissue stains strongly for adipsin; interest-
ingly, the adipsin signal further extends into the lymphocytic
cluster, where it displays a membrane pattern similar to the two
surface markers B220 and CD3, suggesting that adipsin binds to
receptors present on lymphocytes of both subgroups.
In contrast, a typical lymphoid aggregate residing in the gastric
epithelium of an unprotected colonized stomach (Fig. 4B) shows
an almost inverse staining pattern: clearly, the vast majority
(90%) of lymphocytes belong to the B subtype, as would be
expected from a B cell lymphoproliferative disorder. A small but
significant number of T cells can also be detected that have
previously been shown to be H. pylori-specific and essential for
the antigen-dependent proliferation of B cells in MALT lym-
phoma (34). In contrast to the clusters typical of protected
stomachs, MALT aggregates do not stain with an adipsin-
specific antibody, indicating that the proposed cross-talk be-
tween lymphoid and adipose tissue is restricted to protected
stomachs and correlates with protection.
Discussion
Understanding the protective mechanism of any vaccination
protocol is an essential prerequisite in developing a rational
approach to future vaccine optimization and design. The con-
ventional method of elucidating the mechanistic action of a
vaccine is to analyze the effector functions of a small number of
well studied cell types at the systemic level, i.e., in body fluids and
ex vivo. This approach may not be suitable when mucosal
immunization strategies are investigated, because a localized
response at the site of potential pathogen entry or colonization
may be more efficient and crucial at clearing such an infection
than a systemic response.
By generating hypotheses from gene expression profiles of
stomachs of vaccinated animals and testing them by immuno-
histochemistry, we have put special emphasis on studying the
target site of a Helicobacter vaccine. Whereas H. pylori can
persistently colonize the mucus lining of human stomachs for
decades and is perfectly adapted to this niche, it has no genetic
attributes to invade deeper tissues or to enter the bloodstream.
Therefore, unlike other mucosal surface colonizers (Neisseria
meningitidis, Streptococcus pneumoniae, or Haemophilus influ-
enzae), H. pylori never becomes systemic. The segregation of
animals into the three distinct branches representing controls,
colonized, and protected animals, respectively (Fig. 1), dem-
onstrates a profound effect of both Helicobacter infection and
whole-cell vaccination on gastric gene expression profiles and
indicates a strong localized response to the vaccine. Only one
previous study has provided evidence for a localized gastric B
cell response by measuring antigen-specific IgA and IgG in
biopsy specimens of vaccinated individuals who had received
a combination of killed H. pylori whole-cell vaccine and mutant
LTR192G (35).
Our comparison of protected and unprotected or control
mice establishes a link between the production and secretion
of adipokines and a protective response. One of these factors,
adipsin, could furthermore be shown to bind to the surfaces of
lymphocytes that are organized in clusters and embedded in
adipose tissue of protected stomachs (Fig. 4A) implying that
cross-talk occurs between the two cell types. Indeed, the
paracrine relationships between adipose and lymphoid tissues,
both of which can be found in close proximity, i.e., in the
perinodal depots and the omentum, have recently been a
matter of intense research (33, 36–40). The omentum is a
bilayered sheet of mesothelial cells that consists in large part
of adipocytes and connects the stomach, spleen, pancreas, and
transverse colon. It contains aggregates of immune cells
(‘‘milky spots’’) that are believed to play a role in natural
immunity (39). A special population of B cells (termed B1
cells) homes to the omentum through the interaction of the
chemokine CXCL13 with its receptor on the B1 cell surface,
CXCR5, and is believed to play a prominent role in natural
antibody production (40). Indeed, CXCL13/ mice are defi-
cient in mounting an antiphosphorylcholine response against
an i.p. injected streptococcal vaccine (40). Whether the ag-
gregates we find surrounding the stomachs protected from
Helicobacter infection are part of the omentum structure
remains to be established.
Adipocytes themselves are increasingly no longer viewed only
as the primary site for whole body energy storage but may need
Fig. 3. Histological comparison of stomachs representative of each group of animals [control (A), immunizedprotected (B), infected (C), and immunized
unprotected (D)]. The sections were stained with hematoxylineosin and examined at 20. The thin arrows point to fat tissue in control and protected stomachs,
and the thick arrow points to a cluster of lymphocytes embedded in the fat tissue.
12292  www.pnas.orgcgidoi10.1073pnas.1635231100 Mueller et al.
to be redefined as a major endocrine cell type that releases
hormones in response to extracellular stimuli or changes in
metabolic status.
The best-studied adipokine to date is leptin, which has
complex functions in the regulation of immunity and inf lam-
mation (36). In experimental animals, leptin levels are acutely
increased by inf lammatory stimuli such as lipopolysaccharide
and proinf lammatory cytokines (41, 42), which in turn up-
regulate the production of Th-1-specific cytokines (43). The
functions of other members of the adipokine family are less
well understood. Adiponectin and resistin are antagonists
mediating insulin sensitivity and resistence, respectively (44,
45). Adipsin, also known as adipocyte complement factor D
precursor, is a component of the alternative complement
pathway, has serine protease activity, and is secreted into the
bloodstream (46).
In our study, all three adipokines are positively coregulated
in stomachs protected against Helicobacter (Fig. 2). Several
protective mechanisms based on the sum of the above-
mentioned findings are conceivable. (i) Soluble factors se-
creted by adipocytes spread through the epithelium into the
stomach lumen and directly mediate a protective effect by
neutralizing Helicobacter, adipsin being the most likely candi-
date in conjunction with antigen-specific mucosal IgA, the
secretion of which has been shown to be triggered by a very
similar vaccine protocol in humans (35). (ii) Secreted adipo-
cyte factors play an indirect role by stimulating the effector
functions of resident T cell populations. This proposition is
supported by numerous studies demonstrating an essential role
of CD4 T cells in the protection against Helicobacter (12, 15,
47). Molecular cross-talk is likely to occur in both directions,
because activated lymphocytes secrete cytokines that in turn
activate perinodal adipose tissue by stimulating increased
lipolysis both in vitro (48) and in vivo (49). (iii) Antigen-specific
T and B cells residing in fat-embedded clusters act in concert
to neutralize Helicobacter, and the observed increase in fat
Fig. 4. Immunohistochemical staining for antigens specific for cell types potentially involved in a protective immune response. Four sequential sections were
cut from paraffin-embedded tissue, stained with the indicated antibodies, and examined at 40. A fat-embedded lymphocytic cluster typical of protected
stomachs is shown in A, and a lymphoid aggregate typical of MALT tissue in infected mice is shown in B.









tissue characteristic of protected stomachs is a consequence
rather than a cause of protection.
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